We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

History

AC Immune’s history is built on excellence in science and strong leadership in the field of diseases involving misfolded proteins. Since 2003, we have been dedicated to improving the lives of patients suffering from Alzheimer’s and other neurodegenerative diseases. All programs in our pipeline originate from our two proprietary technology platforms.

2016

Initial Public Offering (IPO) on NASDAQ

2016

Genentech milestone payment 2 (anti-Tau antibody)

2016

Biogen research and development collaboration for diagnostics in neurodegenerative diseases

2015

Nestlé Institute of Health Science research collaboration for Tau diagnostic assay

2015

Genentech milestone payment 3 (crenezumab)

2015

Genentech milestone payment 1 (anti-Tau antibody)

2015

Janssen Pharmaceuticals licensing agreement for anti-Tau therapeutic vaccine ($509 million)

2014

Piramal Imaging licensing agreement for anti-Tau diagnostic (significant value)

2012

Genentech licensing agreements for anti-Tau antibody ($418 million)

2011

Genentech milestone payment 2 (crenezumab)

2009

E&Y Entrepreneur of the Year
WEF Technology Pioneer

2009

Bayer Schering collaboration for brain imaging taken over by Piramal Imaging

2008

Genentech milestone payment 1 (crenezumab)

2006

Genentech licensing agreements for anti-Abeta antibody ($300 million)

2003

Foundation of AC Immune

2016

Initial Public Offering (IPO) on NASDAQ

2016

Genentech milestone payment 2 (anti-Tau antibody)

2016

Biogen research and development collaboration for diagnostics in neurodegenerative diseases

2015

Nestlé Institute of Health Science research collaboration for Tau diagnostic assay

2015

Genentech milestone payment 3 (crenezumab)

2015

Genentech milestone payment 1 (anti-Tau antibody)

2015

Janssen Pharmaceuticals licensing agreement for anti-Tau therapeutic vaccine ($509 million)

2014

Piramal Imaging licensing agreement for anti-Tau diagnostic (significant value)

2012

Genentech licensing agreements for anti-Tau antibody ($418 million)

2011

Genentech milestone payment 2 (crenezumab)

2009

E&Y Entrepreneur of the Year
WEF Technology Pioneer

2009

Bayer Schering collaboration for brain imaging taken over by Piramal Imaging

2008

Genentech milestone payment 1 (crenezumab)

2006

Genentech licensing agreements for anti-Abeta antibody ($300 million)

2003

Foundation of AC Immune

Partnerships
Financing / Milestone Payments
Other Milestones